If you have been reading about Angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-11. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
According to generally accepted cosmology theory, only isotopes of hydrogen and helium, traces of some isotopes of lithium and beryllium, and perhaps some boron, were created at the Big Bang, while all other nuclides were synthesized later, in stars and supernovae, and in interactions between energetic particles such as cosmic rays, and previously produced nuclides. (See nucleosynthesis for details of the various processes thought responsible for isotope production.) The respective abundances of isotopes on Earth result from the quantities formed by these processes, their spread through the galaxy, and the rates of decay for isotopes that are unstable. After the initial coalescence of the Solar System, isotopes were redistributed according to mass, and the isotopic composition of elements varies slightly from planet to planet. This sometimes makes it possible to trace the origin of meteorites.
==== Opioid receptors ==== CPA has been found to bind to several of the opioid receptors, including the μ-, δ-, and κ-opioid receptor subtypes. However, this binding is very weak relative to its other actions (IC50 for inhibition of [3H]diprenorphine binding = 1.62 ± 0.33 μM). It has been suggested that activation of opioid receptors might be involved in the sedation that is reportedly sometimes seen with high doses of CPA or in its reported effectiveness in the treatment of cluster headaches.
If areas were depopulated of Neanderthals as a consequence of climate change (specifically Heinrich event 4) or a natural disaster (the Campanian Ignimbrite eruption), Neanderthals may not have been as fast as modern humans in recolonising.
The kanji phrase 銀杏 ginkyō meaning 'silver apricot' had been attested in Chinese herbology literature such as 日用本草 (Daily Use Materia Medica) (1329) and Compendium of Materia Medica 本草綱目 published in 1578; 銀杏 was particular terminology used during the Song dynasty for tributary reasons in place of the then contemporary 鴨脚 ("duckfeet", from its leaves) in northeast China where it commonly grew. The older Chinese name for this plant is 銀果, meaning "silver fruit", pronounced yínguǒ in Mandarin or ngan-gwo in Cantonese, the current commonly used names are 白果 (bái guǒ) meaning 'white fruit'. Despite its spelling based on this complicated etymology, "ginkgo" is usually pronounced , which has given rise to the common alternative spelling "gingko". The spelling pronunciation is also documented in some dictionaries.
Sources: en.wikipedia.org
This process involves the strategic addition of second-phase particles within a ceramic matrix, optimizing their shape, size, and distribution to direct and control crack propagation. This approach enhances fracture toughness, paving the way for the creation of advanced, high-performance ceramics in various industries.
Southern Ohio Medical Center (or SOMC) is a 216-bed 501(C)(3) not-for-profit hospital in Portsmouth, Ohio. It provides emergency and surgical care, as well as other health care services. SOMC employs 2,600 full-time employees and part-time employees, has a medical staff of more than 140 physicians and specialists, and is supported by approximately 800 volunteers. In 2020, Fortune magazine ranked Southern Ohio Medical Center at number 22 of their Fortune List of the Top 100 Companies to Work For based on an employee survey of satisfaction.
==== Chlorine dioxide ==== Chlorine dioxide can come from tablets or be created by mixing two chemicals together. It is more effective than iodine or chlorine against giardia, and although it has only low to moderate effectiveness against cryptosporidium, iodine and chlorine are ineffective against this protozoan. The cost of chlorine dioxide treatment is higher than the cost of iodine treatment.
Sources: en.wikipedia.org
==== Aqueous suspensions ==== Progesterone has been found to have a considerably longer duration of action by intramuscular injection when administered in the form of a microcrystalline aqueous suspension (crystal sizes of 0.02–0.1 mm) than as an oil solution. Whereas a single intramuscular injection of 25 to 350 mg progesterone in oil solution has a duration of 2 to 6 days in terms of clinical biological effect in the uterus in women, a single intramuscular injection of 50 to 300 mg microcrystalline progesterone in aqueous suspension has a duration of 7 to 14 days. As a result, intramuscular progesterone in oil solution is given once every 1 to 3 days at typical clinical doses, whereas intramuscular microcrystalline progesterone in aqueous suspension can be given once weekly or at even longer intervals. The duration of microcrystalline aqueous suspensions is dependent both on drug concentration and on crystal size. A larger needle size is needed for aqueous suspensions of steroids to allow the crystals to pass through the needle lumen. A 20- or 21-gauge needle has been reported to be suitable for the injection of aqueous suspensions of microcrystalline progesterone. Formulations of microcrystalline progesterone in aqueous suspension for long-lasting depot use via intramuscular injection were on the market in the 1950s under a variety of brand names including Flavolutan, Luteosan, Lutocyclin M, and Lutren. Another preparation is Agolutin Depot, which was introduced by 1960 and appears to remain marketed in the Czech Republic and Slovakia today.
Fox, Sidney W. (1957). Introduction to protein chemistry. New York: Wiley. Fox, Sidney W. (1965). The origins of prebiological systems and of their molecular matrices. New York: Acad. Pr. Fox, Sidney W.; Duane L Rohlfing, Aleksandr Ivanovich Oparin (1972). Molecular evolution: prebiological and biological. New York: Plenum Press. Fox, Sidney W., Klaus Dose; with a foreword by A. Oparin (1977). Molecular evolution and the origin of life (Rev. ed. ed.). New York: M. Dekker. Fox, Sidney W. (1984). Individuality and determinism: chemical and biological bases. New York: Plenum Press. Ho, edited by Mae-Wan; Fox, Sidney W. (1988). Evolutionary processes and metaphors. Chichester: Wiley. pp. 333. ISBN 0-471-91801-6. Fox, Sidney W. (1988). The emergence of life: Darwinian evolution from the inside. Basic Books.
== Poiseuille flow through some non-circular cross-sections == Joseph Boussinesq derived the velocity profile and volume flow rate in 1868 for rectangular channel and tubes of equilateral triangular cross-section and for elliptical cross-section. Joseph Proudman derived the same for isosceles triangles in 1914. Let G = −dp/dx be the constant pressure gradient acting in direction parallel to the motion. The velocity and the volume flow rate in a rectangular channel of height 0 ≤ y ≤ h and width 0 ≤ z ≤ l are
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.